INSP — Inspire Medical Systems, Inc. Stock Price, Chart & AI Report

Positive Jun 16, 2026 • 12:00 UTC GlobeNewswire Inc. • Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study

Inspire Medical Systems presented new clinical data at SLEEP 2026 demonstrating the effectiveness of its Inspire V hypoglossal nerve stimulation system for obstructive sleep apnea treatment. Key findings include significant reductions in hypoxic burden, improved cardiovascular outcomes compared to CPAP therapy, and higher patient adherence rates. The company also published studies identifying predictors for therapy eligibility and presented results from its 5,000-patient ADHERE registry showing 62% median AHI reduction.

INSP obstructive sleep apnea hypoglossal nerve stimulation Inspire V system clinical evidence cardiovascular outcomes CPAP comparison patient adherence

Sentiment note

Company presented multiple peer-reviewed studies demonstrating clinical superiority of its Inspire therapy over CPAP, including better patient adherence (93% vs 56% at 30 days), improved cardiovascular outcomes, reduced hypoxic burden, and successful product innovation with the Inspire V system showing 20.4% faster implant times and superior respiratory sensing capabilities.

Neutral Jun 12, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight

Inspire Medical Systems announced that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026 at 10:00 a.m. Eastern Time. The company, which develops minimally invasive solutions for obstructive sleep apnea treatment, will present via live webcast with a replay available for two weeks.

INSP obstructive sleep apnea neurostimulation technology medical device investor conference minimally invasive treatment

Sentiment note

The article is a factual announcement of a conference presentation participation. While conference presentations can indicate investor engagement and market confidence, this is routine corporate communication without material business updates, financial performance changes, or strategic developments that would warrant positive or negative sentiment.

Negative May 5, 2026 • 12:34 UTC Benzinga • Rishabh Mishra

Stock Market Today: Dow, S&P 500, Nasdaq Futures Rise As Traders Monitor US-Iran Ceasefire— Duolingo, Pinterest, AMD In Focus (UPDATED)

U.S. stock futures rose on Tuesday following President Trump's announcement of 'Project Freedom' to reopen commercial shipping through the Strait of Hormuz, amid US-Iran tensions. Key movers included Duolingo (down 12.77% despite beating estimates due to weak guidance), Pinterest (up 16.59% on strong Q1 results), AMD (up 1.94% ahead of earnings), and Inspire Medical Systems (down 21.04% after narrowing revenue guidance). Analysts remain optimistic on tech stocks driven by AI investments and strong corporate earnings.

DUOL PINS ON AMD stock market US-Iran ceasefire Project Freedom Strait of Hormuz

Sentiment note

Stock plunged 21.04% after narrowing full-year revenue guidance to $825-$875M (down 4-10% vs 2025), signaling significant weakness in future revenue expectations.

Neutral Apr 6, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Inspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026

Inspire Medical Systems announced it will release Q1 2026 financial results on May 4, 2026, followed by a management conference call at 5:00 p.m. ET. The company will discuss financial performance and recent business developments. A webcast will be available for investors, with a replay archived for two weeks.

INSP Q1 2026 earnings financial results conference call obstructive sleep apnea neurostimulation technology investor relations

Sentiment note

The article is a routine earnings announcement and conference call notification. While the company showed 12% Q4 revenue growth and 14% full year 2025 growth (positive indicators), the main article focuses on procedural details of the upcoming earnings release rather than substantive business developments or forward-looking statements that would warrant a more positive or negative sentiment.

Positive Mar 26, 2026 • 17:35 UTC Investing.com • David Wagner

These 9 Oversold Stocks Are Significantly Undervalued - Perfect Time to Buy?

The article identifies 9 oversold US stocks trading 30.7% to 66.3% below estimated fair value amid market volatility driven by Middle East tensions and inflation concerns. Using a value investing strategy based on sharp year-to-date declines, proximity to 52-week lows, oversold RSI signals, and undervaluation metrics, the analysis highlights stocks with strong fundamentals that have been excessively sold off, presenting potential rebound opportunities for patient investors.

UPWK INSP oversold stocks value investing undervalued stocks market volatility Middle East tensions inflation

Sentiment note

Develops neurostimulation devices for sleep apnea in a fast-growing, largely untapped market. Despite strong growth and healthy margins, stock declined due to cautious outlooks. Represents a value growth opportunity with solid fundamentals and room for expansion.

Negative Jan 5, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Inspire Medical Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) alleging that the company made materially false and misleading statements regarding market demand for Inspire V and its readiness for product launch. The lawsuit covers investors who purchased securities between August 6, 2024 and August 4, 2025. The law firm is seeking to recover damages for alleged violations of federal securities laws.

INSP class action lawsuit securities fraud Inspire V market demand product launch investor harm federal securities laws

Sentiment note

The company is the defendant in a securities fraud class action lawsuit alleging materially false and misleading statements about product demand and launch readiness, which resulted in investor losses and potential significant financial liability.

Negative Jan 4, 2026 • 12:08 UTC GlobeNewswire Inc. • Bleichmar Fonti & Auld Llp

INSP FINAL DEADLINE: Inspire Medical Systems, Inc. Shareholders are Reminded of the Pending Securities Fraud Lawsuit – Investors with Losses Notified to Contact BFA Law

A class action securities fraud lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) alleging the company misled investors about its Inspire V device launch readiness. The company failed to prepare clinicians and payors for the rollout, resulting in significant delays and weak demand. On August 4, 2025, Inspire disclosed the launch faced an 'elongated timeframe' and reduced 2025 earnings guidance by over 80%, causing the stock to drop 32% from $129.95 to $87.91 per share. The deadline for investors to request lead plaintiff status is January 5, 2026.

INSP securities fraud class action lawsuit Inspire V launch earnings guidance reduction stock price drop FDA approval sleep apnea device

Sentiment note

The company is facing a securities fraud lawsuit for allegedly misleading investors about the Inspire V launch readiness. The device launch experienced significant delays, weak demand, and undisclosed operational challenges. The company reduced 2025 earnings guidance by over 80%, resulting in a 32% stock price decline. These factors indicate serious operational and legal challenges.

Negative Jan 3, 2026 • 17:07 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gauzy Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GAUZ

Rosen Law Firm is reminding investors in Gauzy Ltd., Klarna Group plc, and Inspire Medical Systems, Inc. about upcoming deadlines to join securities class action lawsuits. The firm is seeking lead plaintiffs for cases involving alleged false statements and material omissions by company defendants.

GAUZ KLAR INSP securities class action lead plaintiff deadline investor rights false statements material omissions

Sentiment note

Company is subject to a securities class action lawsuit with investors having losses in excess of $100,000, indicating material adverse events or alleged misconduct affecting shareholder value.

Negative Jan 3, 2026 • 16:26 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Klarna Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KLAR

Rosen Law Firm has filed securities class action lawsuits against multiple companies. The primary case involves Klarna Group plc, alleging the company made false statements in its September 2025 IPO registration statement by understating risks related to loss reserves for buy-now-pay-later loans. The firm is seeking lead plaintiffs with a February 20, 2026 deadline. Similar class actions have been filed against Inspire Medical Systems and agilon health.

KLAR INSP AGL securities class action IPO false statements loss reserves buy-now-pay-later

Sentiment note

Subject of a securities class action lawsuit with investors having losses in excess of $100,000, indicating material misstatements or omissions.

Negative Jan 3, 2026 • 16:00 UTC GlobeNewswire Inc. • Rosen Law Firm

INSP DEADLINE MONDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Inspire Medical Systems, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 5 Deadline in Securities Class Action - INSP

Rosen Law Firm announces a securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP) for investors who purchased stock between August 6, 2024 and August 4, 2025. The lawsuit alleges that defendants misrepresented key facts about the Inspire V sleep apnea device, including actual market demand and launch readiness. The lead plaintiff deadline is January 5, 2026.

INSP securities class action Inspire Medical Systems Inspire V device misrepresentation lead plaintiff deadline investor losses

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations and non-disclosures regarding the Inspire V device's market demand and launch readiness, resulting in investor losses.

Negative Jan 2, 2026 • 19:04 UTC GlobeNewswire Inc. • Hagens Berman

INSP 3-DAY DEADLINE ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut

Hagens Berman has filed a securities class action lawsuit against Inspire Medical Systems (INSP) alleging the company concealed critical operational failures in its Inspire V device launch, including Medicare billing software delays and excess inventory of the older Inspire IV model. The alleged concealment led to a $42.04 stock price drop (32.4% decline) and an over 80% EPS guidance cut. The class period covers purchases between August 6, 2024, and August 4, 2025, with a Lead Plaintiff deadline of January 5, 2026.

INSP securities fraud class action lawsuit operational failures Medicare billing inventory glut stock price decline guidance cut

Sentiment note

Company faces securities fraud allegations for concealing operational failures related to Inspire V launch, including Medicare software delays and inventory issues. Stock declined 32.4% ($42.04 drop) and EPS guidance was slashed over 80%, indicating severe business and investor confidence deterioration.

Negative Jan 2, 2026 • 16:59 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

INSPIRE MEDICAL URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inspire Medical Systems, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Inspire Medical Systems (INSP) for allegedly making false statements about the Inspire V product launch. The company failed to disclose poor demand, excess provider inventory, incomplete training and onboarding, and delayed billing capabilities. Inspire Medical reduced 2025 earnings guidance by over 80%, causing a 32% stock price decline. Investors who purchased shares between August 6, 2024 and August 4, 2025 can join the lawsuit.

INSP class action lawsuit Inspire V launch failure misleading statements poor demand inventory surplus earnings guidance reduction stock price decline

Sentiment note

The company is facing a class action lawsuit for allegedly making false and misleading statements about the Inspire V launch. The product launch failed due to poor demand and incomplete infrastructure, leading to an 80%+ earnings guidance reduction and a 32% stock price decline, resulting in significant investor losses.